Reprogramming the tumor immune microenvironment via antibody-drug conjugates - PubMed
2 days ago
- #Precision medicine
- #Antibody-drug conjugate
- #Tumor microenvironment
- Antibody-drug conjugates (ADCs) are revolutionizing oncology but face challenges due to tumor microenvironment (TME) heterogeneity.
- TME-targeted ADCs aim to modulate immunosuppressive cellular interactions and stromal components to overcome tumor evasion.
- The review covers design strategies, clinical progress, and challenges of TME-targeted ADCs, based on literature from 2015-2025.
- Future directions include AI-driven spatial omics for biomarker-led selection and tailored therapy based on 'TME phenotypes'.
- Emerging platforms like immunostimulatory antibody conjugates (ISACs) and bispecific ADCs will address single-target limitations.
- Regulatory approvals for TME-targeted ADCs in 'cold' tumors are anticipated within five years, serving as priming agents for immunotherapy.
- Within ten years, TME-targeted ADCs may be used in neoadjuvant settings to normalize the tumor ecosystem before surgery.
- Personalized ADC combinations tailored to individual immune landscapes will be key to overcoming adaptive resistance and achieving long-term remission.